The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners
Latest from The Tisch Cancer Institute at Mount Sinai
ADC Sequencing
August 22, 2024
Video
Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.
Management of Emetogenicity of Antibody-Drug Conjugates
August 15, 2024
Video
Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.
Managing Hematologic AEs Associated with ADC Treatments
August 15, 2024
Video
A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.
Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC
August 12, 2024
Video
Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.
Dr Jagannath on the Potential Utility of Linvoseltamab in R/R Multiple Myeloma
August 12, 2024
Video
Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.
Paramountcy of Molecular Testing Is Increasing in Early-Stage NSCLC
August 07, 2024
Article
Fred R. Hirsch, MD, PhD, discusses the role of molecular testing in non–small cell lung cancer.
Dr Sen on the Goal to Identify Actionable Biomarkers of Interest in SCLC
July 30, 2024
Video
Triparna Sen, PhD, discusses the importance of identifying actionable or targetable biomarkers for the management of small cell lung cancer.
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
July 25, 2024
Video
Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.
Cancer Hijacks Your Bone Marrow and Your Immune System: What Are You Going to Do About It?
June 19, 2024
Video
Thomas Marron, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses the ways cancer attacks the bone marrow and immune system.
Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma
June 14, 2024
Video
Sundar Jagannath, MBBS, discusses outcomes with linvoseltamab vs teclistamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma
June 07, 2024
Article
Linvoseltamab elicited outcomes equivalent to those seen with teclistamab in patients with triple-class exposed relapsed/refractory multiple myeloma.
Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma
May 16, 2024
Video
Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.
Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma
May 14, 2024
Video
Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.
The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma
May 13, 2024
Article
Following the consensus that the risk-benefit assessments for the proposed indications for cilta-cel and ide-cel were favorable during the March 15, 2024, FDA ODAC meeting, both BCMA-targeted CAR T-cell therapies received approvals moving them up in the treatment paradigm for relapsed or refractory multiple myeloma.
Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma
May 03, 2024
Video
Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.
Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
April 25, 2024
Article
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma
April 25, 2024
Video
Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.
Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma
April 19, 2024
Video
Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.
Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma
April 08, 2024
Article
Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets
Dr Zamarin on Recent Updates in Endometrial Cancer
April 02, 2024
Video
Dmitriy Zamarin, MD, PhD, discusses the most recent advances in gynecologic cancer management, particularly in endometrial cancer.